Volume Growth and Revenue Performance
Second quarter sales were 1% higher than the prior year, driven by a volume growth of 6%. The growth portfolio exhibited a high single-digit increase, confirming strong expectations for new active ingredients.
Strong Performance in EMEA and Latin America
The EMEA region experienced strong growth due to higher volume sales of herbicides and branded Cyazypyr. Latin America also saw a slight revenue increase as the region concluded the 2024-2025 growing season.
Cost Efficiencies and Improved EBITDA
Adjusted EBITDA for the second quarter was $207 million, 2% higher than the prior year, driven by lower costs attributed to COGS tailwinds from lower raw materials, better fixed cost absorption, and restructuring actions.
Registration and Launch of New Products
Received registration for fluindapyr herbicide containing Isoflex active in Great Britain, with sales anticipated to begin in August. Initial sales of Dodhylex active have commenced, with meaningful sales expected by 2027.